Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | DUT | P33316 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21602127 | 0.86 | CRBN (0.44) | CRBNPKMDDB1DUTPOLB | |
| SCHEMBL21919776 | 0.84 | CRBN (0.46) | CRBNPKMDDB1DUTPOLB | |
| SCHEMBL21418838 | 0.82 | ALDH1A1 (0.32) | PKMPOLBJAK2JAK1TYK2 | |
| SCHEMBL23621035 | 0.80 | ALDH1A1 (0.54) | CRBNPKMHSD17B10 | |
| SCHEMBL2719765 | 0.80 | CRBN (0.54) | CRBNPKMDDB1DUTPOLB | |
| SCHEMBL20194521 | 0.80 | CRBN (0.46) | CRBNPKMDDB1DUTPOLB | |
| SCHEMBL19187082 | 0.79 | CRBN (0.44) | CRBNPKMDDB1DUTPOLB | |
| SCHEMBL18892946 | 0.78 | PKM (0.44) | CRBNPKMDDB1DUTPOLB | |
| SCHEMBL18892908 | 0.78 | PKM (0.44) | CRBNPKMDDB1DUTPOLB | |
| SCHEMBL1344880 | 0.77 | CRBN (0.50) | CRBNPKMDDB1DUTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385725-A1 | UNA AMIDITES AND USES THEREOF | Atrium Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| US-10738072-B1 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2020-08-11 | — | — | US | disclosed |
| US-5545547-A | SYNERGISTIC MIXTURE CONTAINING DEPOLYNERASE | KOLATTUKUDY PAPPACHAN (US) | 1996-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385725-A1 | UNA AMIDITES AND USES THEREOF | NCL, PNP, NASP | CRBN 2370/4885PKM 1361/4885DDB1 692/4885 |
| US-10738072-B1 | Nucleotide analogues | NUDT1, POLN, TYMP | CRBN 3827/4885PKM 3367/4885DDB1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.